The Sirolimus Eluting Coronary Stent System is a new-generation drug-eluting stent (DES) designed to deliver superior outcomes in the treatment of coronary artery disease (CAD). With its ultra-thin metallic platform and controlled release of Sirolimus, the stent ensures optimal vessel scaffolding, enhanced flexibility, and significant reduction in restenosis rates.
Drug Coating:
Sirolimus, a potent immunosuppressive and anti-proliferative agent, inhibits smooth muscle cell proliferation and neointimal hyperplasia.
This controlled drug delivery minimizes the risks of in-stent restenosis (ISR) and ensures long-term patency.
Key Features:
Material: High-strength alloy (Cobalt Chromium / Platinum Chromium / Stainless Steel – depending on model).
Drug: Sirolimus – proven efficacy in reducing restenosis and need for repeat revascularization.
Strut Thickness: Ultra-thin struts for faster healing and minimal vessel injury.
Polymer Coating: Biocompatible polymer allows sustained and uniform drug release.
Deliverability: Flexible design with superior trackability through tortuous vessels.
Clinical Outcome: Demonstrated reduction in major adverse cardiac events (MACE) and late stent thrombosis.
Indications:
Patients with coronary artery stenosis requiring percutaneous coronary intervention (PCI).
Effective for de novo lesions in native coronary arteries, including small vessels, long lesions, and complex anatomies.
Benefits for Patients & Physicians:
Reduces risk of restenosis and stent thrombosis.
Promotes faster endothelialization and safe vessel healing.
Ensures long-term clinical efficacy and patient safety.
Easy and precise stent deployment for interventional cardiologists.
Reviews
There are no reviews yet.